drugset / Trial / NCT07584954
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
Phase 1
Recruiting
90 enrolled
Jun Zhou
Anyang Tumor Hospital · collabFudan University · collabFujian Cancer Hospital · collabHunan Cancer Hospital · collabShandong Cancer Hospital and Institute · collabShanghai Pulmonary Hospital, Shanghai, China · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate a novel cytotoxic anti-PD-L1, IUAb190708, for the treatment of tumor
Timeline
- Start
- 2024-06-18
- Primary completion
- 2028-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IUAb190708 | Monoclonal antibody | 0.2 mg/kg | Intravenous |
| Subject | IUAb190708 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | IUAb190708 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | IUAb190708 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | IUAb190708 | Monoclonal antibody | 15 mg/kg | Intravenous |
Indications
No indication recorded.